Clinical bottom line
Artificial intelligence (AI) applications analyzing tumor immune cell metabolic reprogramming represent a promising, yet still emerging, approach to refining pathological assessment and potentially guiding immunotherapy strategies. Current evidence indicates that AI-driven integration of metabolic signatures from immune cells within the tumor microenvironment can enhance understanding of immune evasion mechanisms and tumor-immune interactions. However, clinical utility remains investigational, with validation needed in diverse tumor types and clinical cohorts before routine adoption.
What the evidence shows
Metabolic reprogramming of immune cells in the tumor microenvironment is increasingly recognized as a critical determinant of immune cell function and tumor immune evasion. Dendritic cells (DCs), T cells, and macrophages undergo distinct metabolic shifts that modulate their activation states and antitumor efficacy (Plebanek et al., 2020; Sung et al., 2022). For example, DCs may shift toward glycolysis or oxidative phosphorylation depending on tumor-derived signals, influencing antigen presentation and immune tolerance (Plebanek et al., 2020).
AI approaches leveraging multiomics datasets, including metabolomics and transcriptomics, have been applied to characterize these metabolic states at high resolution. Liu et al. (2026) performed a bibliometric and exploratory clinical analysis highlighting AI’s role in mapping immune cell metabolic reprogramming, identifying mechanistic hotspots that correlate with tumor progression and response to immunotherapy. Similarly, Öztürk et al. (2026) emphasize how AI models can integrate complex immunometabolic data to predict immune cell activation and dysfunction within tumors.
Sung et al. (2022) demonstrated that cell type-specific metabolic profiling combined with AI algorithms can stratify tumor immune microenvironments, potentially predicting immunotherapy responsiveness. This approach may identify metabolic vulnerabilities amenable to therapeutic targeting or serve as biomarkers for patient selection.
Emerging nanovaccine strategies also exploit metabolic reprogramming of DCs to enhance antitumor immunity, underscoring the translational potential of understanding immune metabolism [6]. Bhattacharya et al. (2026) further discuss epigenetic reprogramming intertwined with metabolic changes, suggesting AI could integrate multi-layered data for comprehensive tumor microenvironment profiling.
Caveats and uncertainty
Despite promising findings, the clinical application of AI in predicting pathological features from tumor immune cell metabolic reprogramming is nascent. Most studies remain preclinical or exploratory, often limited by small sample sizes, heterogeneous tumor types, and lack of standardized metabolic assays. The complexity of immune metabolism and its dynamic nature pose challenges for reproducibility and interpretation.
AI model generalizability is uncertain, as training datasets may not capture the full spectrum of tumor heterogeneity or immune states across patient populations. Additionally, metabolic signatures can be influenced by systemic factors unrelated to the tumor, complicating specificity.
Integration of metabolic data with other omics layers and clinical parameters is still under development. The causal relationships between metabolic changes and immune dysfunction require further mechanistic validation. Finally, regulatory and workflow considerations for implementing AI-based metabolic profiling in pathology laboratories remain unresolved.
How this may change practice
If validated, AI-driven analysis of tumor immune cell metabolic reprogramming could augment traditional pathology by providing functional insights into the tumor immune microenvironment beyond morphology and immunohistochemistry. This may enable more precise stratification of patients for immunotherapies, identification of novel metabolic targets, and monitoring of treatment response.
Pathologists might incorporate metabolic biomarkers derived from AI models into diagnostic reports, guiding multidisciplinary decision-making. Furthermore, such approaches could facilitate personalized immunometabolic interventions, potentially improving outcomes in cancers resistant to current therapies.
However, widespread clinical adoption will require robust prospective studies, standardized protocols, and integration with existing diagnostic workflows. Education on interpreting metabolic AI outputs will be essential for pathologists and oncologists.